Advanced liver Fibrosis Considerably Increases COVID-19 Mortality Risk, New Study Finds
Table of Contents
A extensive French registry of nearly 1,220 patients reveals that pre-existing liver damage is a critical factor in COVID-19 outcomes, with advanced fibrosis emerging as the leading predictor of short-term mortality.
The COVID-19 virus,has tragically claimed over 7 million lives globally,including 168,000 in France. new research underscores the heightened vulnerability of individuals with chronic liver disease (CLD) to the virus,as underlying liver conditions can exacerbate the severity of COVID-19. A notable proportion – between 20% and 65% – of patients infected with SARS-CoV-2 exhibit liver test abnormalities, which are demonstrably linked to more severe illness.
Largest Real-World Cohort Confirms Key risk Factor
A recent, large-scale study conducted by the French Liver society evaluated 1,219 patients with CLD who contracted SARS-CoV-2. This represents the largest “real-life” cohort analyzed to date, providing robust data on the interplay between liver health and COVID-19 prognosis.The findings, published in Scientific Reports in January 2025, definitively confirmed that advanced liver fibrosis was the primary autonomous factor predicting COVID-19-related mortality in the short term.This held true irrespective of a patient’s Child-Pugh score, a common assessment of liver disease severity.
“The study clearly demonstrates that the degree of liver scarring is a critical determinant of outcome,” one analyst noted.
Age and Obesity Also contribute to risk
While advanced fibrosis emerged as the most significant risk factor, age also played a substantial role in increasing vulnerability to fatal COVID-19 outcomes. Moreover, obesity was identified as the sole comorbidity independently associated with death in a multivariate analysis, suggesting a complex interplay between metabolic health and viral severity.
Unexpected resilience in Transplant and Autoimmune Hepatitis Patients
Interestingly, the research revealed a surprising trend: liver transplant recipients did not experience a higher rate of mortality compared to the general population. Researchers attribute this to the restoration of liver function following transplantation. Similarly, patients with autoimmune hepatitis showed no increased risk, indicating that immunosuppression alone does not necessarily worsen COVID-19 outcomes in individuals with CLD.
Implications for clinical Care and Vaccination Strategies
The study highlighted instances of cytolytic hepatitis – inflammation of the liver – occurring in some patients, but crucially, without progressing to acute liver failure, even in severe COVID-19 cases. While factors like alcohol use, MASLD (Metabolic Associated Steatohepatitis), and primary liver tumors were associated with poorer outcomes in initial analyses, only advanced fibrosis and age remained statistically significant when accounting for multiple variables.
These findings strongly advocate for prioritizing COVID-19 vaccination for patients with compensated cirrhosis and implementing close monitoring of individuals with advanced fibrosis during infection.The registry also revealed that limited access to ICU beds in certain regions may have contributed to higher mortality rates, emphasizing the urgent need for equitable healthcare access for vulnerable CLD populations.
Prioritizing Early Intervention and Targeted Management
this comprehensive registry provides invaluable insights into how chronic liver disease influences COVID-19 prognosis. The data underscores that while advanced fibrosis significantly elevates mortality risk, patients who have undergone liver transplantation or have autoimmune hepatitis may not face an elevated risk. These results support the implementation of targeted clinical management strategies and reinforce the importance of prioritizing vaccination and early intervention for patients with high-risk liver conditions.
Reference: Blaise L et al. COVID-19 and chronic liver disease: results from the 1219 patients French registry. Sci Rep. 2025;15(1):34869.
